[關(guān)鍵詞]
[摘要]
肺炎是一種常見的感染性疾病,其中重癥肺炎致病性高、死亡率高。現(xiàn)階段臨床上治療肺炎的藥物相對較多,抗生素類藥物的濫用現(xiàn)象也較為嚴(yán)重,給肺炎患者的治療及預(yù)后均帶來較大影響。中藥以多靶點(diǎn)起效、不良反應(yīng)低等特點(diǎn)在治療肺炎方面發(fā)揮出越來越重要的作用。注射用丹參多酚酸具有抑制炎癥、抗氧化應(yīng)激、調(diào)節(jié)免疫和調(diào)節(jié)腎素-血管緊張素系統(tǒng)(RAS)等作用,通過對該藥的藥效學(xué)及丹參類制劑臨床的應(yīng)用研究進(jìn)展進(jìn)行綜述,對其治療肺炎的可行性進(jìn)行探討,以期為肺炎的有效治療提供參考和依據(jù)。
[Key word]
[Abstract]
Pneumonia is a common infectious disease, severe pneumonia is characterized by high pathogenicity and high mortality. At the present stage, there are many medicine for treating pneumonia, but the abuse of antibiotics is serious, so it will have a greater impact on the treatment and recovery of pneumonia patients. Traditional Chinese medicine is playing an increasingly important role in the treatment of pneumonia due to its multiple targets and low adverse reactions. According to our previous studies, Salvianolic Acids for Injection (SAFI) has many functions including anti-inflammation, anti-oxidative stress and regulation of immunityand Andrenin-angiotensin System (RAS). In this present study, we summarized the related efficacy and clinical studies of SAFI and salvia miltiorrhiza preparation, as well as the feasibility of its application inthepneumonia patients. So aimed to provide evidence and theoretical guidancefor the application of SAFI in pneumonia patients.
[中圖分類號]
R259;R285.6
[基金項(xiàng)目]
天津市科技重大專項(xiàng)與工程“注射用丹參多酚酸臨床再評價(jià)研究”(18ZXXYSY00120)